431 related articles for article (PubMed ID: 30610101)
1. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
2. Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis.
Li B; Xu H; Han H; Song S; Zhang X; Ouyang L; Qian C; Hong Y; Qiu Y; Zhou W; Huang M; Zhuang W
Oncogene; 2018 Oct; 37(41):5508-5519. PubMed ID: 29895968
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
Huang T; Chen Y; Zeng Y; Xu C; Huang J; Hu W; Chen X; Fu H
BMC Cancer; 2021 Jul; 21(1):844. PubMed ID: 34294084
[TBL] [Abstract][Full Text] [Related]
4. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
5. Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma.
Li W; Zhang L; Guo B; Deng J; Wu S; Li F; Wang Y; Lu J; Zhou Y
Mol Cancer; 2019 Feb; 18(1):22. PubMed ID: 30736860
[TBL] [Abstract][Full Text] [Related]
6. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
7. Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma.
Luo Y; Gui R
Turk J Haematol; 2020 Nov; 37(4):248-262. PubMed ID: 32812415
[TBL] [Abstract][Full Text] [Related]
8. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
9. Exosomal miR-182 derived from bone marrow mesenchymal stem cells drives carfilzomib resistance of multiple myeloma cells by targeting SOX6.
Long S; Long S; He H; Luo L; Liu M; Ding T
J Orthop Surg Res; 2023 Dec; 18(1):937. PubMed ID: 38062424
[TBL] [Abstract][Full Text] [Related]
10. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
11. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
12. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
13. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
14. Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis.
Liu Y; Zou R; Wang Z; Wen C; Zhang F; Lin F
Biochem J; 2018 Nov; 475(22):3629-3638. PubMed ID: 30341166
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT.
Zhang X; Sai B; Wang F; Wang L; Wang Y; Zheng L; Li G; Tang J; Xiang J
Mol Cancer; 2019 Mar; 18(1):40. PubMed ID: 30866952
[TBL] [Abstract][Full Text] [Related]
16. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
17. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of circulating exosomal miRNAs in multiple myeloma.
Manier S; Liu CJ; Avet-Loiseau H; Park J; Shi J; Campigotto F; Salem KZ; Huynh D; Glavey SV; Rivotto B; Sacco A; Roccaro AM; Bouyssou J; Minvielle S; Moreau P; Facon T; Leleu X; Weller E; Trippa L; Ghobrial IM
Blood; 2017 Apr; 129(17):2429-2436. PubMed ID: 28213378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
